Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

Cancer Cell(2022)10.1016/j.ccell.2022.10.001Source: DataRank Database

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy is a research paper published in Cancer Cell (2022). On theSindex it has a DataRank of 0.778. It has been cited 178 times.

N/A

0.778DataRank · unranked

Scored on demand from live citation data

Open Access178 citations

Download PDF

Cite:

Linked data & code

geo uniprot nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: bronzeTopics (24)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)Annotations (3)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.778

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (31)

Joseph A. Tandurella ORCID,Jessica Gai,Qingfeng Zhu ORCID,Su Jin Lim ORCID,Dwayne L. Thomas ORCID

Live enrichment

PubMed:36306792 PMC:PMC9669212

Deutsche Forschungsgemeinschaft

Grant: KI 2437/2-1

National Institutes of Health

Grant: P50 CA062924

National Institutes of Health

Grant: R01 CA169702

National Institutes of Health

Grant: R01 CA197296

National Cancer Institute

Grant: P30 CA006973

NCI NIH HHS

Grant: U01 CA253403

NCI NIH HHS

Grant: T32 CA126607

NCI NIH HHS

Grant: K08 CA259456

NCI NIH HHS

Grant: R50 CA243627

NCI NIH HHS

Grant: P01 CA247886

NCI NIH HHS

Grant: T32 CA009110

Johns Hopkins University

Bristol-Myers Squibb

bronzeLicense: cc-by-nc-nd

publisherhttp://www.cell.com/article/S1535610822004925/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610822004925?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610822004925?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9669212

Europe_PMChttps://europepmc.org/articles/PMC9669212

Fields of Study

HumansPancreatic NeoplasmsAdenocarcinomaNeoadjuvant TherapyTumor MicroenvironmentNivolumabCarcinoma, Pancreatic Ductal

MeSH Terms

HumansAdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsNeoadjuvant TherapyTumor MicroenvironmentNivolumab

Keywords

CD137Pancreatic cancerIL-8Vaccine TherapyTh17Rna SequencingTumor-associated NeutrophilsImmune Checkpoint InhibitorAnti-pd-1 AntibodyMultiplex Immunohistochemistry

Additional file 2 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.25556642.v1figshare

Additional file 2 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.25556642figshare

Additional file 1 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.25953303.v1figshare

Additional file 1 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.25953303figshare

Additional file 2 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.25953355.v1figshare

Additional file 2 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.25953355figshare

Additional file 4 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702515.v1figshare

Additional file 4 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702515figshare

Additional file 5 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702518.v1figshare

Additional file 5 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702518figshare

Additional file 6 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702521.v1figshare

Additional file 6 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702521figshare

Additional file 7 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702524.v1figshare

Additional file 7 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702524figshare

Additional file 8 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702527.v1figshare

Additional file 8 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702527figshare

Additional file 9 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702533.v1figshare

Additional file 9 of Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

10.6084/m9.figshare.26702533figshare

Additional file 3 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.26728495.v1figshare

Additional file 3 of PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

10.6084/m9.figshare.26728495figshare